BNP Paribas Asset Management
XENE icon

BNP Paribas Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

BNP Paribas Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78M Buy
1,342,028
+281,807
+27% +$13M 0.09% 229
2025
Q4 		$47.5M Buy
1,060,221
+389,964
+58% +$16.4M 0.05% 317
2025
Q3 		$26.9M Buy
670,257
+9,175
+1% +$323K 0.07% 281
2025
Q2 		$20.7M Sell
661,082
-42,713
-6% -$1.39M 0.05% 343
2025
Q1 		$23.6M Buy
703,795
+40,091
+6% +$1.52M 0.06% 297
2024
Q4 		$26M Buy
663,704
+224,630
+51% +$9.29M 0.06% 286
2024
Q3 		$17.3M Buy
439,074
+17,953
+4% +$724K 0.04% 334
2024
Q2 		$16.4M Buy
421,121
+4,385
+1% +$175K 0.04% 331
2024
Q1 		$17.9M Buy
+416,736
New +$19.2M 0.05% 320

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Asset Management's XENE Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 27% in Q1 2026, buying an estimated $13M and bringing the position to 1,342,028 shares worth $78M. The position accounts for 0.09% of the portfolio, ranked #229.

BNP Paribas Asset Management first reported a position in XENE in Q1 2024 and has held it in 9 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • BNP Paribas Asset Management held 1,342,028 shares of Xenon Pharmaceuticals worth $78M as of Q1 2026.
  • BNP Paribas Asset Management bought 281,807 Xenon Pharmaceuticals shares in Q1 2026, an estimated $13M.
  • Xenon Pharmaceuticals made up 0.09% of BNP Paribas Asset Management's portfolio in Q1 2026, its #229 holding.
  • BNP Paribas Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.